Tanvex BioPharma, Inc.
TWSE:6541.TW
63.2 (TWD) • At close November 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Tanvex BioPharma, Inc. |
Symbool | 6541.TW |
Munteenheid | TWD |
Prijs | 64 |
Beurswaarde | 10,500,544,000 |
Dividendpercentage | 0% |
52-weken bereik | 35.05 - 80 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yun Yen F.A.C.P., FACP, M.D., Ph.D. |
Website | https://www.tanvex.com |
An error occurred while fetching data.
Over Tanvex BioPharma, Inc.
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (TWD)
Cijfers zijn in miljoenen (TWD)